Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,313 Shares of Company Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,313 shares of Palvella Therapeutics stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the sale, the chief operating officer owned 2,165 shares of the company’s stock, valued at $269,715.70. The trade was a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, September 16th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.24, for a total transaction of $654,936.48.
• On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA traded down $1.29 during mid-day trading on Friday, hitting $125.10. The stock had a trading volume of 161,792 shares, compared to its average volume of 259,770. The company has a 50 day moving average of $143.08 and a two-hundred day moving average of $134.55. Palvella Therapeutics, Inc. has a twelve month low of $68.96 and a twelve month high of $161.38. The firm has a market cap of $1.80 billion, a PE ratio of -25.90 and a beta of -0.27.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts predict that Palvella Therapeutics, Inc. will post -6.41 EPS for the current fiscal year.

Analyst Ratings Changes

PVLA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. William Blair initiated coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $209.79.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV purchased a new stake in Palvella Therapeutics in the first quarter valued at $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics during the 2nd quarter worth about $35,000. Sterling Capital Management LLC grew its position in Palvella Therapeutics by 907.7% during the 3rd quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after purchasing an additional 354 shares during the period. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics during the 2nd quarter valued at about $69,000. Finally, Quantbot Technologies LP purchased a new position in shares of Palvella Therapeutics during the 2nd quarter valued at about $71,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.